BTK and B-cell chronic lymphocytic leukemia: The study by Buhimschi et al. [87], is particularly interesting as it included the first analysis of effects of BTK-targeted PROTACs on Cys481Ser mutant BTK, acquisition of which (as described above) is thought to be a major cause of ibrutinib resistance in CLL patients.